Kirjojen hintavertailu. Mukana 11 342 296 kirjaa ja 12 kauppaa.
Kirja.info

Kirjahaku

Etsi kirjoja tekijän nimen, kirjan nimen tai ISBN:n perusteella.

189 tulosta hakusanalla Monocle

Monoclonal Antibodies

Monoclonal Antibodies

Heddy Zola

CRC Press Inc
1987
sidottu
This book describes, in detail, tested techniques for the produc-tion and use of monoclonal antibodies. It covers those aspects of interest to all scientists working with monoclonal antibodies and presents methods in a step-by-step format for easy refer-ence. The text serves as a laboratory manual; and discusses rationale behind each method, and the choices between methods. It also provides a rational basis where several alternative methods are available.
Vertaile hintoja
Monoclonal Antibodies in Cancer

Monoclonal Antibodies in Cancer

Humana Press Inc.
1985
sidottu
This represents the third volume in a series on cancer markers pub- lished by the Humana Press. The first volume, published in 1980, stressed the relationship of development and cancer as reflected in the production of markers by cancer that are also produced by normal cells during fetal development. The concept that cancer represents a problem of differentiation was introduced by Barry Pierce in describing differenti- ation of teratocarcinomas. Highlighted were lymphocyte markers, alphafetoprotein, carcinoembryonic antigen, ectopic hormones, enzymes and isozymes, pregnancy proteins, and fibronectin. The second volume, published in 1982 and coedited with Britta Wahren, focused on the diagnostic use of oncological markers in human cancers, which were systematically treated on an organ by organ basis. At that time, the application of monoclonal antibodies to the identification of cancer markers was still in a very preliminary stage. A general introduc- tion to monoclonal antibodies to human tumor antigens was given there by William Raschke, and other authors included coverage of those mark- ers then detectable by monoclonal antibodies in their chapters.
Vertaile hintoja
Monoclonal Antibody Protocols

Monoclonal Antibody Protocols

William C. Davis

Humana Press Inc.
1995
nidottu
Since the initial description of techniques to immortalize anti­ body-producing B-lymphocytes by fusion with tissue culture-adapted myeloma cells, methods have been developed to produce monoclonal antibodies of defined specificity in multiple animal species. Stable hybrids can be readily produced in mice using a number of myeloma and hybridoma cell lines. To obviate the problem of identifying fusion partners in other animal species, xenohybrids have been produced using B-lymphocytes from the relevant species and mouse myeloma cells. The use of xenohybrids has minimized the problem of obtain­ ing stable antibody-producing hybrids in all species examined thus far. Although alternative techniques are being developed to produce monoclonal antibodies by molecular methods, hybridoma technol­ ogy will remain the technology of choice for producing monoclonal antibodies for a variety of applications in research and industry. The objective of Monoclonal Antibody Protocols is to provide investigators with a set of methods for producing and using mono­ clonal antibodies in biomedical, agricultural, and biological sciences. The book is not intended to provide methodology for all possible applications, but rather a series of methods presented in an easy-- follow format that can be used by new and established investiga­ tors, graduate and postgraduate fellows, and technical staff.
Vertaile hintoja
Monoclonal Antibodies and Breast Cancer

Monoclonal Antibodies and Breast Cancer

Kluwer Academic Publishers
1985
sidottu
Breast cancer, being a disease with very high prevalence in the female population, has permanently attracted the attention of biologists, biochemists, pathologists, surgeons, and oncologists. In the U.S. alone approximately 120,000 new cases are diagnosed and 37,000 deaths a year are recorded as an outcome. Early diagnosis, clear cut prognosis and the hope of new therapeutic approaches has spurred the enthusiasm of researchers, who with the advent of newer methodologies, tried to employ it in different approaches to the breast cancer patient. In spite of the efforts devoted towards the creation of new approaches, reagents and procedures taking advantage of special characteristics of the breast tissue were slow to come. In general, most diagnostic and prognostic techniques were those shared and applied to other carcinomas. In the early seventies we discovered the first sets of antigens associated with breast epithelial tissue both in the mouse and the human. The recognition of such group of molecules, present in the milk fat globule membrane, gave impetus to several studies in these areas. These mammary cell surface antigens proved useful in several diagnostic approaches such as radioimaging, histochemical and serum assay procedures. However, the apparently inherent limitations of polyclonal antibodies reduced the impact of these novel approaches.
Vertaile hintoja
Monoclonal Antibody Therapy of Human Cancer

Monoclonal Antibody Therapy of Human Cancer

Kluwer Academic Publishers
1985
sidottu
KENNETH A. FOON and ALTON C. MORGAN, JR. Passive immunotherapy using heteroantisera for the treatment of cancer in animals and humans has been studied for over 50 years. Attempts have been made to treat animal tumors with sera from immunized syngeneic, allogeneic, or xenogeneic animals. A number of studies of passive immunotherapy using heterologous antisera in humans have also been performed. These studies have generally been attempted in patients with large tumor burdens, and as would be expected, results have been transient at best. A wide variety of solid tumors as well as leukemias and lym- phomas have been treated with antisera raised in sheep, horses, rabbits, and goats. Problems such as anaphylaxis, serum sick- ness, and severe cytopenias have been encountered with these antisera. There are a number of potential mechanisms by which unconju- gated antibodies might be cytotoxic to tumor cells. Antibodies bound to the cell surface membrane of tumor cells may lead to cell lysis by complement-dependent or antibody-dependent cellu- lar cytotoxicity. Circulating tumor cells bound by antibody may be more susceptible to phagocytosis by the reticuloendothelial system. Antibody bound to the cell surface membrane of tumor cells may enhance immunogenicity of the tumor cell leading to activation of the host's immune system.
Vertaile hintoja
Monoclonal Hybridoma Antibodies

Monoclonal Hybridoma Antibodies

John G.R. Hurrell

CRC Press
2017
sidottu
The first section of this volume is aimed to provide a comprehensive review of the many varied and often empirically derived techniques and procedures currently in use to produce monoclonal hybridoma cell lines and to characterize the antibodies secreted. The goal has been achieved with the chapter contributed by Zola and Brookes who, as each step in the process of hybridoma production and antibody characterisation is reviewed, have provided an experimental procedure found to be satisfactory in their laboratory.The second section of this volume is designed to provide a review of areas in which monoclonal hybridoma antibodies have been of particular advantage. This is a rapidly advancing field which could not be thoroughly reviewed in a single volume.
Vertaile hintoja
Monoclonal Gammopathies and the Kidney

Monoclonal Gammopathies and the Kidney

Springer-Verlag New York Inc.
2003
sidottu
Table 1 Comparison of MIDD and immunoglobulinic amyloidosis MIDD Amyloidosis Presentation Multivisceral or predominant involvement of an organ (kidney) Underlying disease Monoclonal immunoproliferative disorders, mostly myeloma. Monoclonal bone marrow plasma cell populations without overt malignancy. Possibility of 'non-secretory' forms. Deposits by EM (Granular) non-organized Fibrillar (13 pleated sheets) Spectrum LCDD : L chains, most K, either AL-amyloidosis : fragments (?)* of or apparently enlarged, normal-sized normal-sized or apparently enlarged or short. Frequent glycosylation L chains most A. Frequent and polymeration. glycosylation.Abnormal susceptibility to proteolysis. LHCDD : associated H chains Cases with associated short H chains (short by biosynthesis by biosynthesis experiments. experiments). HCDD: short H chains. AH-amyloidosis : short H chains. L chain isotypy V K IV predominance. VAVI C A3predominance. V region mutations Yes Yes *Found in necropsy material; whether they exist in vivo is doubtful. 3 After Preud'homme et al. AL-amyloidosis). Therefore, we believe' that the term MIDD should be restricted to this pathological entity, whatever the Ig content of the deposits, light 4 5 ) or both (LHCDD ). However, the chains (LCDD), heavy chains (HCDD New York group used the denomination MIDD for both Randall's disease and immunoglobulinic amyloidosis'S". The two processes have many features in common (Table I) and they can be associated in the same patients.
Vertaile hintoja
Monoclonal Antibodies in Cancer

Monoclonal Antibodies in Cancer

Humana Press Inc.
2011
nidottu
This represents the third volume in a series on cancer markers pub- lished by the Humana Press. The first volume, published in 1980, stressed the relationship of development and cancer as reflected in the production of markers by cancer that are also produced by normal cells during fetal development. The concept that cancer represents a problem of differentiation was introduced by Barry Pierce in describing differenti- ation of teratocarcinomas. Highlighted were lymphocyte markers, alphafetoprotein, carcinoembryonic antigen, ectopic hormones, enzymes and isozymes, pregnancy proteins, and fibronectin. The second volume, published in 1982 and coedited with Britta Wahren, focused on the diagnostic use of oncological markers in human cancers, which were systematically treated on an organ by organ basis. At that time, the application of monoclonal antibodies to the identification of cancer markers was still in a very preliminary stage. A general introduc- tion to monoclonal antibodies to human tumor antigens was given there by William Raschke, and other authors included coverage of those mark- ers then detectable by monoclonal antibodies in their chapters.
Vertaile hintoja
Monoclonal Antibodies and Breast Cancer

Monoclonal Antibodies and Breast Cancer

Springer-Verlag New York Inc.
2012
nidottu
Breast cancer, being a disease with very high prevalence in the female population, has permanently attracted the attention of biologists, biochemists, pathologists, surgeons, and oncologists. In the U.S. alone approximately 120,000 new cases are diagnosed and 37,000 deaths a year are recorded as an outcome. Early diagnosis, clear cut prognosis and the hope of new therapeutic approaches has spurred the enthusiasm of researchers, who with the advent of newer methodologies, tried to employ it in different approaches to the breast cancer patient. In spite of the efforts devoted towards the creation of new approaches, reagents and procedures taking advantage of special characteristics of the breast tissue were slow to come. In general, most diagnostic and prognostic techniques were those shared and applied to other carcinomas. In the early seventies we discovered the first sets of antigens associated with breast epithelial tissue both in the mouse and the human. The recognition of such group of molecules, present in the milk fat globule membrane, gave impetus to several studies in these areas. These mammary cell surface antigens proved useful in several diagnostic approaches such as radioimaging, histochemical and serum assay procedures. However, the apparently inherent limitations of polyclonal antibodies reduced the impact of these novel approaches.
Vertaile hintoja
Monoclonal Antibody Therapy of Human Cancer

Monoclonal Antibody Therapy of Human Cancer

Springer-Verlag New York Inc.
2012
nidottu
KENNETH A. FOON and ALTON C. MORGAN, JR. Passive immunotherapy using heteroantisera for the treatment of cancer in animals and humans has been studied for over 50 years. Attempts have been made to treat animal tumors with sera from immunized syngeneic, allogeneic, or xenogeneic animals. A number of studies of passive immunotherapy using heterologous antisera in humans have also been performed. These studies have generally been attempted in patients with large tumor burdens, and as would be expected, results have been transient at best. A wide variety of solid tumors as well as leukemias and lym- phomas have been treated with antisera raised in sheep, horses, rabbits, and goats. Problems such as anaphylaxis, serum sick- ness, and severe cytopenias have been encountered with these antisera. There are a number of potential mechanisms by which unconju- gated antibodies might be cytotoxic to tumor cells. Antibodies bound to the cell surface membrane of tumor cells may lead to cell lysis by complement-dependent or antibody-dependent cellu- lar cytotoxicity. Circulating tumor cells bound by antibody may be more susceptible to phagocytosis by the reticuloendothelial system. Antibody bound to the cell surface membrane of tumor cells may enhance immunogenicity of the tumor cell leading to activation of the host's immune system.
Vertaile hintoja
Monoclonal Antibodies

Monoclonal Antibodies

Springer-Verlag New York Inc.
2012
nidottu
On August 7, 1975, Kohler and Milstein published in Nature (256:495) a report describing "Continuous cultures of fused cells secreting antibody of predefined specificity. " Their report has become a classic and has already had a profound effect on basic and applied research in biology and medicine. By the time the first Workshop on Lymphocyte Hybridomas (Current Topics in Microbiology and Im­ munology 81, 1978) was held on April 3-5, 1978, in Bethesda, Maryland, investi­ gators from many laboratories had made hybrids between plasmacytomas and spleen cells from immunized animals and had obtained monoclonal antibodies reacting with a broad variety of antigenic determinants. At the time Kohler and Milstein introduced this new technology, the editors of this volume were involved in the production of antisera against differentiation antigens (K. B. B. ), histocompatibility antigens (T. ]. McK. ), and human tumor­ associated antigens (R. H. K. ). Because of the potential usefulness of monoclonal antibodies in these areas, we each began production of hybridomas and analysis of the resulting monoclonal reagents. One of the most interesting aspects of participation in the early stages of the development and application of hybrid­ oma technology has been observing how the implications of the initial observa­ tions gradually spread first among the practitioners of immunology and immu­ nogenetics, and then to other areas of the biological sciences, such as developmental biology, biochemistry, human genetics, and cell and tumor biology.
Vertaile hintoja
Monoclonal Antibodies and Functional Cell Lines

Monoclonal Antibodies and Functional Cell Lines

Springer-Verlag New York Inc.
2012
nidottu
This volume serves as a follow-up to our previous book, MonoclonalAntibodies­ Hybridomas: A New Dimension in Biological Analyses. We continue the theme of monoclonal antibodies and their applications, attempting to cover some of the areas not covered in the previous volume. We again include an appendix de­ scribing methods useful to those who ar-e beginning to apply these techniques in their own laboratories. This volume will be followed by another concentrating on the combination of monoclonal antibody techniques with molecular genetic techniques to study structure/function relationships at the level of both the gene and gene product. Roger H. Kennett Kathleen B. Bechtol Philadelphia, Pennsylvania Thomas J. McKearn Princeton, New Jersey IX Acknowledgments Roger Kennett acknowledges the patience and support of his wife, Carol, and his family, friends, and colleagues during the work on this volume, and again thanks, above all, the Lord, Jesus Christ. Kathleen Bechtol wishes to thank colleagues and friends for their support and understanding during the months of preparation of this volume. Tom McKearn acknowledges and thanks his wife, Pat, and his family for their support and encouragement. Xl Contents PART I INTRODUCTION 1 Introduction: Reflections on Nine Years of Monoclonal Antibodies from Hybridomas 3 ROGER H. KENNETT, KATHLEEN B. BECHTOL, AND THOMAS J. McKEARN 1. Biotechnology'S "Coming of Age". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 II. Monoclonal Antibodies-An Overview of Applications. . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 III. Commercialization of Monoclonal Antibody Technology.. . . .. ... . .... .... .. . ... . . 10 References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . 13 . . . . . . . . . . . . . . . . . . . . .
Vertaile hintoja
Monoclonal Antibodies

Monoclonal Antibodies

Humana Press Inc.
2016
nidottu
Monoclonal Antibodies: Methods and Protocols, Second Edition expands upon the previous edition with current, detailed modern approaches to isolate and characterize monoclonal antibodies against carefully selected epitopes. This edition includes new chapters covering the key steps to generate high quality monoclonals via different methods, from antigen generation to epitope mapping and quality control of the purified IgG. Chapters are divided into four parts corresponding to four distinct objectives. Part I covers monoclonal antibody generation, Part II deals with monoclonal antibody expression and purification, Part III presents methods for monoclonal antibody characterization and modification, and Part IV describes selected applications of monoclonal antibodies. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.Authoritative and practical, Monoclonal Antibodies: Methods and Protocols, Second Edition provides crucial initial steps of monoclonal antibody generation and characterization with state-of-the art protocols.
Vertaile hintoja
Monoceros

Monoceros

Suzette Mayr

Coach House Books
2011
pokkari
Winner of the W.O. Mitchell Book Prize Winner of the 2012 Relit Award for Best Novel Longlisted for the 2011 Scotiabank Giller Prize Shortlisted for the Ferro-Grumley Award for LGBT Fiction Shortlisted for the Alberta Literary Award for Best Fiction Shortlisted for the W.O. Mitchell Award for Best Calgary Fiction A Globe and Mail Best Book of 2011 A seventeen-year-old boy, bullied and heartbroken, hangs himself. And although he felt terribly alone, his suicide changes everyone around him. His parents are devastated. His secret boyfriend's girlfriend is relieved. His unicorn- and virginity-obsessed classmate, Faraday, is shattered; she wishes she had made friends with him that time she sold him an Iced Cappuccino at Tim Hortons. His English teacher, mid-divorce and mid-menopause, wishes she could remember the dead student's name, that she could care more about her students than her ex's new girlfriend. Who happens to be her cousin. The school guidance counselor, Walter, feels guilty--maybe he should have made an effort when the kid asked for help. Max, the principal, is worried about how it will reflect on the school. And Walter, who's secretly been in a relationship with Max for years, thinks that's a little callous. He's also tired of Max's obsession with some sci-fi show on TV. And Max wishes Walter would lose some weight and remember to use a coaster. And then Max meets a drag queen named Crepe Suzette. And everything changes. Suzette Mayr is the author of three previous novels: Moon Honey, The Widows, and Venous Hum. The Widows was shortlisted for the Commonwealth Writers' Prize for Best Book in the Canada-Caribbean region, and has been translated into German. Moon Honey was shortlisted for the Georges Bugnet Award for Fiction and the Henry Kreisel Award for Best First Book. Suzette Mayr lives and works in Calgary, Alberta.
Vertaile hintoja
Monoclonal Antibodies

Monoclonal Antibodies

Humana Press Inc.
2007
sidottu
Monoclonal Antibodies: Methods and Protocols examines a collection of state-of-the-art methods that employ monoclonal antibodies in a clinical setting with opening chapters focusing on the gold standard method for generating mouse monoclonal antibodies through hybridoma technology, future methods for engineering recombinant and humanized antibodies, methods for engineering soluble Fc fusion protein, and the use of antibodies and flow cytometry in the quantification of cell signaling proteins. Specific chapters describe how antibodies are used for the diagnosis and classification of hematologic diseases. Subsequent chapters examine the advantages and most recent advances of using bead-based immunoassays, including the ability of bead-based technology to multiplex and analyze several analytes simultaneously, and the use of beads in detecting fusion proteins resulting from chromosomal translocations. Concluding chapters provide additional examples of methodologies that employ monoclonal antibodies. Monoclonal Antibodies: Methods and Protocols provides descriptions of methods that cover a wide spectrum of applications in the field of monoclonal antibodies. This field will continue to expand and provide new and innovative techniques, not only in the laboratory, but also as a basis that complements targeted therapy.
Vertaile hintoja
Monoclonal Antibodies

Monoclonal Antibodies

Nova Science Publishers Inc
2006
sidottu
This new and important international source of information beings together leading-edge research dedicated to monoclonal antibodies. Monoclonal antibodies (MAbs) are: antibodies of exceptional purity and specificity; components of the immune system; able to recognise and bind to a specific antigen. Monoclonal antibodies are currently utilised in many diagnostic procedures, including: measuring protein and drug levels in serum; typing tissue and blood; identifying infectious agents; identifying clusters of differentiation for the classification and follow-up therapy of leukaemias and lymphomas; identifying tumour antigens and auto-antibodies; identifying the specific cells involved in the immune response; identifying and quantifying hormones. For example, monoclonal antibodies (MABs or MOABs) work on cancer cells in the same way natural antibodies work, by identifying and binding to the target cells. They then alert other cells in the immune system to the presence of the cancer cells. MABs are specific for a particular antigen-one designed for a B-cell lymphoma will not work on cells for ovarian cancer cells for example.
Vertaile hintoja
Monoclonal Antibodies

Monoclonal Antibodies

Humana Press Inc.
2010
nidottu
Monoclonal Antibodies: Methods and Protocols examines a collection of state-of-the-art methods that employ monoclonal antibodies in a clinical setting with opening chapters focusing on the gold standard method for generating mouse monoclonal antibodies through hybridoma technology, future methods for engineering recombinant and humanized antibodies, methods for engineering soluble Fc fusion protein, and the use of antibodies and flow cytometry in the quantification of cell signaling proteins. Specific chapters describe how antibodies are used for the diagnosis and classification of hematologic diseases. Subsequent chapters examine the advantages and most recent advances of using bead-based immunoassays, including the ability of bead-based technology to multiplex and analyze several analytes simultaneously, and the use of beads in detecting fusion proteins resulting from chromosomal translocations. Concluding chapters provide additional examples of methodologies that employ monoclonal antibodies. Monoclonal Antibodies: Methods and Protocols provides descriptions of methods that cover a wide spectrum of applications in the field of monoclonal antibodies. This field will continue to expand and provide new and innovative techniques, not only in the laboratory, but also as a basis that complements targeted therapy.
Vertaile hintoja
Monoclonal Antibodies

Monoclonal Antibodies

Humana Press Inc.
2014
sidottu
Monoclonal Antibodies: Methods and Protocols, Second Edition expands upon the previous edition with current, detailed modern approaches to isolate and characterize monoclonal antibodies against carefully selected epitopes. This edition includes new chapters covering the key steps to generate high quality monoclonals via different methods, from antigen generation to epitope mapping and quality control of the purified IgG. Chapters are divided into four parts corresponding to four distinct objectives. Part I covers monoclonal antibody generation, Part II deals with monoclonal antibody expression and purification, Part III presents methods for monoclonal antibody characterization and modification, and Part IV describes selected applications of monoclonal antibodies. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.Authoritative and practical, Monoclonal Antibodies: Methods and Protocols, Second Edition provides crucial initial steps of monoclonal antibody generation and characterization with state-of-the art protocols.
Vertaile hintoja
Monoclonal Antibodies: Important Role in Medical Diagnosis and Therapies

Monoclonal Antibodies: Important Role in Medical Diagnosis and Therapies

American Medical Publishers
2023
sidottu
A monoclonal antibody refers to an antibody formed through cloning a distinctive white blood cell. Antibodies are glycoproteins produced through differentiated B lymphocytes known as plasma cells in response to exposure to antigens. The range of antibody responses to different target antigens occurs due to gene recombination process in the hyper-variable areas of antibodies. Monoclonal antibodies (mAbs) are formed through the similar clones of B lymphocytes in response to a specific antigen. There are numerous properties of mAbs including antigen-binding site region, identical downstream functional effects, protein sequence and binding affinity for their targets. These antibodies are often given through the subcutaneous route. They are helpful in diagnosing various diseases such as cancer and hormonal disorders. These antibodies are also useful in treating various other conditions like asthma and AIDS. This book elucidates the prospective developments with respect to monoclonal antibodies. It presents researches and studies performed by experts across the globe. Scientists and students actively engaged in the therapeutic applications of antibodies will find this book full of crucial and unexplored concepts.
Vertaile hintoja
Monoclonal Antibodies

Monoclonal Antibodies

IntechOpen
2021
sidottu
Immune-based therapies are being studied extensively in a variety of immunological conditions due to their high precision and sensitivity. Monoclonal antibody (mAb) technology is a major advancement in the treatment of several infectious diseases, malignancies, and immunological disorders. This book provides comprehensive information about technologies, characterization, and application of mAbs in the clinic and laboratory.
Vertaile hintoja
123456...10